Detalles de la búsqueda
1.
Influence of acute and chronic kidney failure in rats on the disposition and pharmacokinetics of ZYAN1, a novel prolyl hydroxylase inhibitor, for the treatment of chronic kidney disease-induced anemia.
Xenobiotica
; 48(1): 37-44, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-28042744
2.
Central GLP-1 receptor activation improves cholesterol metabolism partially independent of its effect on food intake.
Can J Physiol Pharmacol
; 94(2): 161-167, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26629909
3.
Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
Can J Physiol Pharmacol
; 92(12): 975-83, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25361428
4.
Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia.
Diabetes
; 64(7): 2609-23, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25633418
5.
Orally active osteoanabolic agent GTDF binds to adiponectin receptors, with a preference for AdipoR1, induces adiponectin-associated signaling, and improves metabolic health in a rodent model of diabetes.
Diabetes
; 63(10): 3530-44, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24848063
6.
Erratum. Pathophysiological Mechanism of Bone Loss in Type 2 Diabetes Involves Inverse Regulation of Osteoblast Function by PGC-1α and Skeletal Muscle Atrogenes: AdipoR1 as a Potential Target for Reversing Diabetes-Induced Osteopenia. Diabetes 2015;64:2609-2623.
Diabetes
; 66(12): 3142-3143, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28982654
Resultados
1 -
6
de 6
1
Próxima >
>>